Alnylam’s givosiran gets FDA priority review for acute hepatic porphyria

This article was originally published here

Givosiran, which has been developed to be subcutaneously administered, targets aminolevulinic acid synthase 1 (ALAS1). According to Alnylam, monthly administration of the investigational RNAi therapeutic can potentially reduce

The post Alnylam’s givosiran gets FDA priority review for acute hepatic porphyria appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply